This content is from: Patents
EPO revokes Broad Institute’s CRISPR patent
The EPO has denied the Broad Institute of MIT and Harvard’s reliance on its US priority provisional application in revoking a CRISPR patent. The institute has already said it will appeal
To access our in-house intelligence please request a trial here.
Read this article – and more – for a 30 day period.
REQUEST ACCESSAre you already an Managing IP subscriber? Login here